Research ArticleAutoimmunity

Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

See allHide authors and affiliations

Science Translational Medicine  06 Mar 2013:
Vol. 5, Issue 175, pp. 175ra30
DOI: 10.1126/scitranslmed.3005166

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

  • The urgent need for randomized clinical trial of rituximab in pemphigus

    This is a long awaited paper by Colliou et al. presenting results of >7-year follow-up study of patients with autoimmune pemphigus treated using rituximab (RTX). Careful examination of the clinical outcome data, however, suggests that the use of RTX does not provide clear advantage over standard treatment, and may even increase the death risk. The most important clinical data of Colliou et al. summarized in Table S1...

    Show More
    Competing Interests: None declared.

Stay Connected to Science Translational Medicine